摘要
目的评价左氧氟沙星联合金刚藤颗粒治疗慢性盆腔炎的临床疗效。方法64例慢性盆腔炎患者采用数字表法随机分成对照组和治疗组,每组32例,对照组给予左氧氟沙星片治疗,治疗组给予左氧氟沙星联合金刚藤颗粒治疗,总疗程均为21d。观察治疗前后两组患者症状、体征变化情况及不良反应,检测治疗前后血清CRP水平,评价临床疗效。结果治疗组症状积分与体征积分均明显低于对照组,差异均有统计学意义[(2.61±2.09)分比(5.32±3.28)分,t=3.941,P=0.000;(1.47±1.02)分比(2.56±2.04)分,t=2.703,P=0.008]。对照组治疗后血清CRP水平为(5.46±1.93)mg/L,明显高于治疗组的(3.76±1.06)ms/L,差异有统计学意义(t=4.367,P=0.000)。治疗组总有效率为96.9%,对照组总有效率为78.1%,两组差异有统计学意义(x2=5.142,P=0.023)。两组治疗期间无明显不良反应。结论两组左氧氟沙星联合金刚藤颗粒能明显改善慢性盆腔炎症状、体征,临床疗效确切,安全性高,值得临床推广应用。
Objeetive To evaluate the clinical effect of levofloxacin combined with Jingangteng particle in the treatment of patients with chronic pelvic inflammatory disease. Methods According to the random number table, sixty - four patients with chronic pelvic inflammatory disease were divided into control group ( n = 32 ) which were treated with levofloxacin and treatment group (n = 32 ) which were treated with levofloxacin and Jingangteng particle for three weeks. The clinical effect, symptoms and signs were evaluated and the adverse reactions between the two groups were observed as well as serum C reactive protein(CRP) were measured before and after treatment. Results The score of symptoms and signs of the treatment group were significantly lower than the control group, the difference was statistically significant [ (2. 61± 2. 09) points vs. (5.32 ± 3.28) points, t = 3. 941, P = 0. 000; ( 1.47 ±1. 02 ) points vs. (2.56 ± 2.04) points, t = 2.703, P = 0.008 1. The level of serum CRP of the control group was (5.46 ± 1.93 ) mg/L, which was statistically higher than (3.76 ±1.06 ) mg/L of the treatment group after treatment, the difference was statistically significant (t =4. 367 ,P =0.000). The total effective rate of the treatment group was 96.9%, which of the control group was 78. 1%, the difference between the two groups were statistically significant ( X2 = 5. 142 ,P = 0. 023 ). There was no significant adverse reactions during the treatment. Conclusion Levofloxacin combined with Jingangteng particle can obviously improve the symptoms and signs of chronic pelvic inflammatory disease, they have good safety and are worthy of clinical popularization and application.
出处
《中国基层医药》
CAS
2016年第1期77-81,共5页
Chinese Journal of Primary Medicine and Pharmacy